TNNT2 and chronic kidney disease: One such approach could be SCr–adjusted hs-cTnT cutoff levels, which has been suggested for patients with CKD.41 Novel immunoassays targeting specific epitopes of cTnT fragments may help to differentiate dynamic cTnT elevations explained mainly by nonischemic from ischemic factors according to potentially different cTnT fragmentation patterns during degradation.33,36,42 However, the clinical utility of such novel assays in AKI remains unknown.